AVE 0991, a non-peptide mimic of angiotensin-(1-7) effects, attenuates pulmonary remodelling in a model of chronic asthma

British Journal of Pharmacology

Volumn 170, Issue 4, 2013, Pages 835-846

  Rodrigues Machado, M G ^a   Magalhaes G S ^a   Cardoso, J A ^a   Kangussu, L M ^a   Murari, A ^a   Caliari, M V ^a   Oliveira, M L ^a   Cara, D C ^a   Noviello, M L M ^a   Marques, F D ^a   Pereira, J M ^a   Lautner, R Q ^a   Santos, R A S ^a   Campagnole Santos, M J ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

airway remodelling; allergic lung inflammation; angiotensin (1 7); asthma; AVE 0991; cytokines; Mas receptor

Indexed keywords

ANGIOTENSIN II; CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 5; N ETHYLCARBAMOYL 3 [4 (5 FORMYL 4 METHOXY 2 PHENYL 1 IMIDAZOLYLMETHYL)PHENYL] 5 ISOBUTYL 2 THIOPHENESULFONAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTHMA; BRONCHUS; CONTROLLED STUDY; DRUG RESPONSE; HEART RIGHT VENTRICLE HYPERTROPHY; INFLAMMATION; LUNG BLOOD VESSEL; LUNG HOMOGENATE; LUNG LAVAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PULMONARY REMODELLING; RESPIRATORY TRACT DISEASE; RESPIRATORY TRACT MUCOSA;

AIRWAY REMODELLING; ALLERGIC LUNG INFLAMMATION; ANGIOTENSIN-(1-7); ASTHMA; AVE 0991; CYTOKINES; MAS RECEPTOR;

AIRWAY REMODELING; ANGIOTENSIN I; ANGIOTENSIN II; ANIMALS; ANTI-ASTHMATIC AGENTS; ASTHMA; BRONCHOALVEOLAR LAVAGE FLUID; BRONCHOCONSTRICTION; CHRONIC DISEASE; CYTOKINES; DISEASE MODELS, ANIMAL; HYPERTROPHY, RIGHT VENTRICULAR; IMIDAZOLES; LUNG; MALE; MICE; MICE, INBRED BALB C; MOLECULAR MIMICRY; OVALBUMIN; PEPTIDE FRAGMENTS; PROTO-ONCOGENE PROTEINS; PULMONARY ARTERY; PULMONARY VEINS; RECEPTORS, G-PROTEIN-COUPLED; TIME FACTORS;

EID: 84885155097     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12318     Document Type: Article

References (49)

1. Alexander SPH, Mathie A, Peters JA, (2011). Guide to Receptors and Channels (GRAC), 5th edition. Br J Pharmacol 164 (Suppl. 1): S1-324.
2. Al-Muhsen S, Johnson JR, Hamid Q, (2011). Remodeling in asthma. J Allergy Clin Immunol 128: 451-462.
3. Barroso LC, Silveira KD, Lima CX, Borges V, Bader M, Rachid M, et al. (2012). Renoprotective effects of AVE0991, a nonpeptide Mas receptor agonist, in experimental acute renal injury. Int J Hypertens 2012: 808726.
4. Bergeron C, Tulic MK, Hamid Q, (2010). Airway remodelling in asthma: from benchside to clinical practice. Can Respir J 17: e85-e93.
5. Botelho LM, Block CH, Khosla MC, Santos RAS, (1994). Plasma angiotensin(1-7) immunoreactivity is increased by salt load, water deprivation, and hemorrhage. Peptides 15: 723-729.
6. Bramley AM, Roberts CR, Schellenberg RR, (1995). Collagenase increases shortening of human bronchial smooth muscle in vitro. Am J Respir Crit Care Med 152: 1513-1517.
7. Bruijnzeel PL, (1994). Eosinophil tissue mobilization in allergic disorders. Ann N Y Acad Sci 725: 259-267.
8. Carlson M, Peterson C, Venge P, (1993). The influence of IL-3, IL-5, and GM-CSF on normal human eosinophil and neutrophil C3b-induced degranulation. Allergy 48: 437-442.
9. Chen H, Tliba O, Van-Besien CR, Panettieri RA Jr, Amrani Y, (2003). TNF-[alpha] modulates murine tracheal rings responsiveness to G-protein-coupled receptor agonists and KCl. J Appl Physiol 95: 864-872.
10. Cho JY, (2011). Recent advances in mechanisms and treatments of airway remodeling in asthma: a message from the bench side to the clinic. Korean J Intern Med 26: 367-383.
11. da Silveira KD, Coelho FM, Vieira AT, Sachs D, Barroso LC, Costa VV, et al. (2010). Anti-inflammatory effects of the activation of the angiotensin-(1-7) receptor, MAS, in experimental models of arthritis. J Immunol 185: 5569-5576.
12. Dimitropoulou C, Drakopanagiotakis F, Chatterjee A, Snead C, Catravas JD, (2009). Estrogen replacement therapy prevents airway dysfunction in a murine model of allergen-induced asthma. Lung 187: 116-127.
13. Du YC, Xu JY, Zhang SJ, (2004). Effects of angiotensin II receptor antagonist on expression of collagen III, collagen V, and transforming growth factor beta1 in the airway walls of sensitized rats. Chin Med J (Engl) 117: 908-912.
14. Durrani SR, Viswanathan RK, Busse WW, (2011). What effect does asthma treatment have on airway remodeling? Current perspectives. J Allergy Clin Immunol 128: 439-448.
15. EL-Hashim AZ, Renno WM, Raghupathy R, Abduo HT, Akhtar S, Benter IF, (2012). Angiotensin-(1-7) inhibits allergic inflammation, via the MAS1 receptor, through suppression of ERK1/2- and NF-kappaB-dependent pathways. Br J Pharmacol 166: 1964-1976.
16. Ferreira AJ, Oliveira TL, Castro MC, Almeida AP, Castro CH, Caliari MV, et al. (2007). Isoproterenol-induced impairment of heart function and remodeling are attenuated by the nonpeptide angiotensin-(1-7) analogue AVE 0991. Life Sci 81: 916-923.
17. Ferreira AJ, Bader M, Santos RA, (2012). Therapeutic targeting of the angiotensin-converting enzyme 2/Angiotensin-(1-7)/Mas cascade in the renin-angiotensin system: a patent review. Expert Opin Ther Pat 22: 567-574.
18. Foster PS, Ming Y, Matthei KI, Young IG, Temelkovski J, Kumar RK, (2000). Dissociation of inflammatory and epithelial responses in a murine model of chronic asthma. Lab Invest 80: 655-662.
19. Girodet PO, Ozier A, Bara I, Tunon de Lara JM, Marthan R, Berger P, (2011). Airway remodeling in asthma: new mechanisms and potential for pharmacological intervention. Pharmacol Ther 130: 325-337.
20. Kidd P, (2003). Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease. Altern Med Rev 8: 223-246.
21. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). NC3Rs Reporting Guidelines Working Group. Br J Pharmacol 160: 1577-1579.
22. Kosaka S, Tamauchi H, Terashima M, Maruyama H, Habu S, Kitasato H, (2011). IL-10 controls Th2-type cytokine production and eosinophil infiltration in a mouse model of allergic airway inflammation. Immunobiology 216: 811-820.
23. Kumar RK, Herbert C, Yang M, Koskinen AM, McKenzie AN, Foster PS, (2002). Role of interleukin-13 in eosinophil accumulation and airway remodelling in a mouse model of chronic asthma. Clin Exp Allergy 32: 1104-1111.
24. Lampinen M, Carlson M, Hakansson LD, Venge P, (2004). Cytokine-regulated accumulation of eosinophils in inflammatory disease. Allergy 59: 793-805.
25. Lautner RQ, Villela DC, Fraga-Silva RA, Silva N, Verano-Braga T, Costa-Fraga F, et al. (2013). Discovery and characterization of alamandine: a novel component of the renin-angiotensin system. Circ Res 112: 1104-1111.
26. Lemos VS, Silva DM, Walther T, Alenina N, Bader M, Santos RAS, (2005). The endothelium-dependent vasodilator effect of the nonpeptide Ang(1-7) mimic AVE 0991 is abolished in the aorta of mas-knockout mice. J Cardiovasc Pharmacol 46: 274-279.
27. Lubel JS, Herath CB, Tchongue J, Grace J, Jia Z, Spencer K, et al. (2009). Angiotensin-(1-7), an alternative metabolite of the renin-angiotensin system, is up-regulated in human liver disease and has antifibrotic activity in the bile-duct-ligated rat. Clin Sci (Lond) 117: 375-386.
28. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
29. McKay S, de Jongste JC, Saxena PR, Sharma HS, (1998). Angiotensin II induces hypertrophy of human airway smooth muscle cells: expression of transcription factors and transforming growth factor-beta1. Am J Respir Cell Mol Biol 18: 823-833.
30. Manso L, Reche M, Padial MA, Valbuena T, Pascual C, (2012). Diagnostic tools assessing airway remodelling in asthma. Allergol Immunopathol (Madr) 40: 108-116.
31. Marques FD, Ferreira AJ, Sinisterra RD, Jacoby BA, Sousa FB, Caliari MV, et al. (2011). An oral formulation of angiotensin-(1-7) produces cardioprotective effects in infarcted and isoproterenol-treated rats. Hypertension 57: 477-483.
32. Marques FD, Melo MB, Souza LE, Irigoyen MC, Sinisterra RD, de Sousa FB, et al. (2012). Beneficial effects of long-term administration of an oral formulation of angiotensin-(1-7) in infarcted rats. Int J Hypertens 2012: 795452.
33. Milanese M, Crimi E, Scordamaglia A, Riccio A, Pellegrino R, Canonica GW, et al. (2001). On the functional consequences of bronchial basement membrane thickening. J Appl Physiol 91: 1035-1040.
34. Palmans E, Kips JC, Pauwels RA, (2000). Prolonged allergen exposure induces structural airway changes in sensitized rats. Am J Respir Crit Care Med 161: 627-635.
35. Pedersen SE, Hurd SS, Lemanske RF Jr, Becker A, Zar HJ, Sly PD, et al. (2011). Global strategy for the diagnosis and management of asthma in children 5 years and younger. Pediatr Pulmonol 46: 1-17.
36. Pinheiro SV, Simoes e Silva AC, Sampaio WO, de Paula RD, Mendes EP, Bontempo ED, et al. (2004). Nonpeptide AVE 0991 is an angiotensin-(1-7) receptor Mas agonist in the mouse kidney. Hypertension 44: 490-496.
37. Saldanha JC, Gargiulo DL, Silva SS, Carmo-Pinto FH, Andrade MC, Alvarez-Leite JI, et al. (2004). A model of chronic IgE-mediated food allergy in ovalbumin-sensitized mice. Braz J Med Biol Res 37: 809-816.
38. Santos RAS, Ferreira AJ, (2006). Pharmacological effects of AVE 0991, a nonpeptide angiotensin-(1-7) receptor agonist. Cardiovasc Drug Rev 24: 239-246.
39. Santos RAS, Simoes e Silva AC, Maric C, Silva DM, Machado RP, de Buhr I, et al. (2003). Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci U S A 100: 8258-8263.
40. Santos RAS, Ferreira AJ, Nadu AP, Braga AN, de Almeida AP, Campagnole-Santos MJ, et al. (2004). Expression of an angiotensin-(1-7)- producing fusion protein produces cardioprotective effects in rats. Physiol Genomics 17: 292-299.
41. Santos RAS, Ferreira AJ, Pinheiro SV, Sampaio WO, Touyz R, Campagnole-Santos MJ, (2005). Angiotensin-(1-7) and its receptor as a potential targets for new cardiovascular drugs. Expert Opin Investig Drugs 14: 1019-1031.
42. Tagaya E, Tamaoki J, (2007). Mechanisms of airway remodeling in asthma. Allergol Int 56: 331-340.
43. Vieira RP, de Andrade VF, Duarte AC, dos Santos AB, Mauad T, Martins MA, et al. (2008). Aerobic conditioning and allergic pulmonary inflammation in mice. II. Effects on lung vascular and parenchymal inflammation and remodeling. Am J Physiol Lung Cell Mol Physiol 295: L670-L679.
44. Wang T, Yin KS, Liu KY, Lu GJ, Li YH, Chen JD, (2008). Effect of valsartan on the expression of angiotensin II receptors in the lung of chronic antigen exposure rats. Chin Med J (Engl) 121: 2312-2319.
45. Wiemer G, Dobrucki LW, Louka FR, Malinski T, Heitsch H, (2002). AVE 0991, a nonpeptide mimic of the effects of angiotensin-(1-7) on the endothelium. Hypertension 40: 847-852.
46. Xia YC, Redhu NS, Moir LM, Koziol-White C, Ammit AJ, Al-Alwan L, et al. (2012). Pro-inflammatory and immunomodulatory functions of airway smooth muscle: emerging concepts. Pulm Pharmacol Ther 26: 64-74.
47. Yang YC, Zhang N, Van Crombruggen K, Hu GH, Hong SL, Bachert C, (2012). Transforming growth factor-beta1 in inflammatory airway disease: a key for understanding inflammation and remodeling. Allergy 67: 1193-1202.
48. Zhang F, Hu H, Xu Q, Ye S, (2010). Different effects of angiotensin II and angiotensin-(1-7) on vascular smooth muscle cell proliferation and migration. PLoS ONE 5: e12323.
49. Zhang WX, Li CC, (2011). Airway remodeling: a potential therapeutic target in asthma. World J Pediatr 7: 124-128.